Metabolic syndrome: Therapeutic considerations

Research output: Chapter in Book/Report/Conference proceedingChapter

33 Citations (Scopus)

Abstract

The metabolic syndrome is a constellation of metabolic risk factors for atherosclerotic cardiovascular disease (ASCVD) occurring in one individual. There are five cardiovascular risk factors that accompany the metabolic syndrome: atherogenic dyslipidemia [elevated apolipoprotein B (apo B), elevated triglyceride, small low-density lipoprotein (LDL) particles, and low high-density lipoprotein (HDL)cholesterol], elevated blood pressure, elevated glucose, a prothrombotic state, and a proinflammatory state. The likelihood of an individual developing metabolic syndrome is enhance by underlying risk factors, notably, obesity, insulin resistance, lack of physical activity, advancing age, and hormonal factors (e.g., androgens and corticosteroids). Besides being at higher risk for ASCVD, persons with the metabolic syndrome are at increased risk for type 2 diabetes. Persons with the metabolic syndrome deserve management in the clinical setting to reduce the risk for both ASCVD and type 2 diabetes. The two major therapeutic strategies for treatment of affected persons are modification of the underlying risk factors and separate drug treatment of the particular metabolic risk factors when appropriate. First-line therapy for underlying risk factors is therapeutic lifestyle changes, i.e., weight loss in obese persons, increased physical activity, and anti-atherogenic diet. These changes will improve all of the metabolic risk factors. Whether use of drugs to reduce insulin resistance is effective, safe, and cost-effective before the onset of diabetes awaits the results of more clinical research. Turning to individual risk components, for atherogenic dyslipidemia, drug therapies that promote lowering of apo B and raise HDL cholesterol will be needed for higher risk patients. Treatment of categorical hypertension with drugs has become standard practice. When hyperglycemia reaches the diabetic level, glucose-lowering agents will become necessary when dietary control is no longer effective, and reduction of a prothrombotic state with low-dose aspirin may be indicated in higher-risk patients.

Original languageEnglish (US)
Title of host publicationHandbook of Experimental Pharmacology
Pages107-133
Number of pages27
Volume170
DOIs
StatePublished - 2005

Publication series

NameHandbook of Experimental Pharmacology
Volume170
ISSN (Print)01712004
ISSN (Electronic)18650325

Fingerprint

Cardiovascular Diseases
Apolipoproteins B
Dyslipidemias
Type 2 Diabetes Mellitus
HDL Cholesterol
Therapeutics
Insulin Resistance
Medical problems
Pharmaceutical Preparations
Drug therapy
Exercise
Atherogenic Diet
Glucose
Age Factors
Hyperglycemia
LDL Cholesterol
Androgens
Aspirin
Life Style
Weight Loss

Keywords

  • Atherogenic dyslipidemia
  • Hyperglycemia
  • Hypertension
  • Insulin resistance
  • Metabolic syndrome
  • Pharmacology therapy
  • Proinflammatory state
  • Prothrombotic state
  • Therapeutic lifestyle changes

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry

Cite this

Grundy, S. M. (2005). Metabolic syndrome: Therapeutic considerations. In Handbook of Experimental Pharmacology (Vol. 170, pp. 107-133). (Handbook of Experimental Pharmacology; Vol. 170). https://doi.org/10.1007/3-540-27661-0-3

Metabolic syndrome : Therapeutic considerations. / Grundy, Scott M.

Handbook of Experimental Pharmacology. Vol. 170 2005. p. 107-133 (Handbook of Experimental Pharmacology; Vol. 170).

Research output: Chapter in Book/Report/Conference proceedingChapter

Grundy, SM 2005, Metabolic syndrome: Therapeutic considerations. in Handbook of Experimental Pharmacology. vol. 170, Handbook of Experimental Pharmacology, vol. 170, pp. 107-133. https://doi.org/10.1007/3-540-27661-0-3
Grundy SM. Metabolic syndrome: Therapeutic considerations. In Handbook of Experimental Pharmacology. Vol. 170. 2005. p. 107-133. (Handbook of Experimental Pharmacology). https://doi.org/10.1007/3-540-27661-0-3
Grundy, Scott M. / Metabolic syndrome : Therapeutic considerations. Handbook of Experimental Pharmacology. Vol. 170 2005. pp. 107-133 (Handbook of Experimental Pharmacology).
@inbook{3a049fd6dc6444daaac165ab3ad3eb6b,
title = "Metabolic syndrome: Therapeutic considerations",
abstract = "The metabolic syndrome is a constellation of metabolic risk factors for atherosclerotic cardiovascular disease (ASCVD) occurring in one individual. There are five cardiovascular risk factors that accompany the metabolic syndrome: atherogenic dyslipidemia [elevated apolipoprotein B (apo B), elevated triglyceride, small low-density lipoprotein (LDL) particles, and low high-density lipoprotein (HDL)cholesterol], elevated blood pressure, elevated glucose, a prothrombotic state, and a proinflammatory state. The likelihood of an individual developing metabolic syndrome is enhance by underlying risk factors, notably, obesity, insulin resistance, lack of physical activity, advancing age, and hormonal factors (e.g., androgens and corticosteroids). Besides being at higher risk for ASCVD, persons with the metabolic syndrome are at increased risk for type 2 diabetes. Persons with the metabolic syndrome deserve management in the clinical setting to reduce the risk for both ASCVD and type 2 diabetes. The two major therapeutic strategies for treatment of affected persons are modification of the underlying risk factors and separate drug treatment of the particular metabolic risk factors when appropriate. First-line therapy for underlying risk factors is therapeutic lifestyle changes, i.e., weight loss in obese persons, increased physical activity, and anti-atherogenic diet. These changes will improve all of the metabolic risk factors. Whether use of drugs to reduce insulin resistance is effective, safe, and cost-effective before the onset of diabetes awaits the results of more clinical research. Turning to individual risk components, for atherogenic dyslipidemia, drug therapies that promote lowering of apo B and raise HDL cholesterol will be needed for higher risk patients. Treatment of categorical hypertension with drugs has become standard practice. When hyperglycemia reaches the diabetic level, glucose-lowering agents will become necessary when dietary control is no longer effective, and reduction of a prothrombotic state with low-dose aspirin may be indicated in higher-risk patients.",
keywords = "Atherogenic dyslipidemia, Hyperglycemia, Hypertension, Insulin resistance, Metabolic syndrome, Pharmacology therapy, Proinflammatory state, Prothrombotic state, Therapeutic lifestyle changes",
author = "Grundy, {Scott M}",
year = "2005",
doi = "10.1007/3-540-27661-0-3",
language = "English (US)",
isbn = "9783540225690",
volume = "170",
series = "Handbook of Experimental Pharmacology",
pages = "107--133",
booktitle = "Handbook of Experimental Pharmacology",

}

TY - CHAP

T1 - Metabolic syndrome

T2 - Therapeutic considerations

AU - Grundy, Scott M

PY - 2005

Y1 - 2005

N2 - The metabolic syndrome is a constellation of metabolic risk factors for atherosclerotic cardiovascular disease (ASCVD) occurring in one individual. There are five cardiovascular risk factors that accompany the metabolic syndrome: atherogenic dyslipidemia [elevated apolipoprotein B (apo B), elevated triglyceride, small low-density lipoprotein (LDL) particles, and low high-density lipoprotein (HDL)cholesterol], elevated blood pressure, elevated glucose, a prothrombotic state, and a proinflammatory state. The likelihood of an individual developing metabolic syndrome is enhance by underlying risk factors, notably, obesity, insulin resistance, lack of physical activity, advancing age, and hormonal factors (e.g., androgens and corticosteroids). Besides being at higher risk for ASCVD, persons with the metabolic syndrome are at increased risk for type 2 diabetes. Persons with the metabolic syndrome deserve management in the clinical setting to reduce the risk for both ASCVD and type 2 diabetes. The two major therapeutic strategies for treatment of affected persons are modification of the underlying risk factors and separate drug treatment of the particular metabolic risk factors when appropriate. First-line therapy for underlying risk factors is therapeutic lifestyle changes, i.e., weight loss in obese persons, increased physical activity, and anti-atherogenic diet. These changes will improve all of the metabolic risk factors. Whether use of drugs to reduce insulin resistance is effective, safe, and cost-effective before the onset of diabetes awaits the results of more clinical research. Turning to individual risk components, for atherogenic dyslipidemia, drug therapies that promote lowering of apo B and raise HDL cholesterol will be needed for higher risk patients. Treatment of categorical hypertension with drugs has become standard practice. When hyperglycemia reaches the diabetic level, glucose-lowering agents will become necessary when dietary control is no longer effective, and reduction of a prothrombotic state with low-dose aspirin may be indicated in higher-risk patients.

AB - The metabolic syndrome is a constellation of metabolic risk factors for atherosclerotic cardiovascular disease (ASCVD) occurring in one individual. There are five cardiovascular risk factors that accompany the metabolic syndrome: atherogenic dyslipidemia [elevated apolipoprotein B (apo B), elevated triglyceride, small low-density lipoprotein (LDL) particles, and low high-density lipoprotein (HDL)cholesterol], elevated blood pressure, elevated glucose, a prothrombotic state, and a proinflammatory state. The likelihood of an individual developing metabolic syndrome is enhance by underlying risk factors, notably, obesity, insulin resistance, lack of physical activity, advancing age, and hormonal factors (e.g., androgens and corticosteroids). Besides being at higher risk for ASCVD, persons with the metabolic syndrome are at increased risk for type 2 diabetes. Persons with the metabolic syndrome deserve management in the clinical setting to reduce the risk for both ASCVD and type 2 diabetes. The two major therapeutic strategies for treatment of affected persons are modification of the underlying risk factors and separate drug treatment of the particular metabolic risk factors when appropriate. First-line therapy for underlying risk factors is therapeutic lifestyle changes, i.e., weight loss in obese persons, increased physical activity, and anti-atherogenic diet. These changes will improve all of the metabolic risk factors. Whether use of drugs to reduce insulin resistance is effective, safe, and cost-effective before the onset of diabetes awaits the results of more clinical research. Turning to individual risk components, for atherogenic dyslipidemia, drug therapies that promote lowering of apo B and raise HDL cholesterol will be needed for higher risk patients. Treatment of categorical hypertension with drugs has become standard practice. When hyperglycemia reaches the diabetic level, glucose-lowering agents will become necessary when dietary control is no longer effective, and reduction of a prothrombotic state with low-dose aspirin may be indicated in higher-risk patients.

KW - Atherogenic dyslipidemia

KW - Hyperglycemia

KW - Hypertension

KW - Insulin resistance

KW - Metabolic syndrome

KW - Pharmacology therapy

KW - Proinflammatory state

KW - Prothrombotic state

KW - Therapeutic lifestyle changes

UR - http://www.scopus.com/inward/record.url?scp=33645754517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645754517&partnerID=8YFLogxK

U2 - 10.1007/3-540-27661-0-3

DO - 10.1007/3-540-27661-0-3

M3 - Chapter

C2 - 16596797

AN - SCOPUS:33645754517

SN - 9783540225690

VL - 170

T3 - Handbook of Experimental Pharmacology

SP - 107

EP - 133

BT - Handbook of Experimental Pharmacology

ER -